menu

A Portrait of Bipolar I Depression: Visualizing Improved Patient Care on World Bipolar Day

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Portrait of Bipolar I Depression: Visualizing Improved Patient Care on World Bipolar Day

close
1.00 credits
1 hour

CME/CE Broadcast Replay

A Portrait of Bipolar I Depression: Visualizing Improved Patient Care on World Bipolar Day
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Bipolar depression remains a burden for patients living with bipolar I disorder. Therefore, faculty experts came together on World Bipolar Day in a call to action to the healthcare community to improve the diagnosis and treatment of bipolar I depression. In this 60-minute activity previously aired as a live broadcast, faculty review the diagnosis and treatment of a patient case, discussing the utility of tools in diagnosis and strategies to overcome common clinical challenges. An overview of treatments recommended for bipolar I depression is also provided.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME/CE activity:

    • Planners (Forefront Collaborative): Valerie Siclari, PhD and Megan Ragan
    • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
    • Faculty Planner: James Edgar Skye

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    Faculty Presenter: Larry Culpepper, MD, MPH

    • Royalty: UpToDate
    • Consulting Fee: AbbVie Pharmaceuticals, Acadia Pharmaceuticals, Allergan Pharmaceuticals, Eisai Pharmaceuticals, Takeda Pharmaceuticals 
    • Advisory Board: AbbVie Pharmaceuticals, Acadia Pharmaceuticals, Allergan Pharmaceuticals, Eisai Pharmaceuticals, Takeda Pharmaceuticals
    • Ownership Interest: M3 Information, LLC
    • Other: Receive payment from Physicians Postgraduate Press as Editor in Chief of the Primary Care Companion for CNS Diseases

    Faculty Presenter: Joseph F. Goldberg, MD, MS 

    • Royalty: American Psychiatric Publishing; Cambridge University Press
    • Consulting Fee: BioXcel; Otsuka; Neurocrine; Sunovion; Sage Pharmaceuticals
    • Speakers Bureau: AbbVie; Intracellular Therapies; Sunovion
    • Advisory Board: Otsuka; Sunovion; Neurocrine

    Faculty Presenter: Andrew A. Nierenberg, MD 

    • Royalty: UpToDate; Guilford Press
    • Consulting Fee: Alkermes; Clexio; Ginger.io; Merck; Neuronetics; NeuroRx; Sage; Sunovion
    • Contracted Research: Fitbit; Myriad

    Faculty Planner: Mary D. Moller, DNP, PhD(h), ARNP, PMHCNS-BC, CPRP, FAAN 

    • Speakers Bureau: Alkermes; Otsuka
    • Advisory Board: Teva

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    The target audience includes psychiatrists, primary care physicians (PCPs), nurse practitioners (NPs), and physician assistants (PAs) who care for patients with bipolar I disorder.

  • Learning Objectives

    Upon completion of this activity, learners should increase their ability to

    1. Distinguish bipolar I depression from unipolar depression earlier in patients.
    2. Incorporate tools to help diagnose bipolar I depression into routine practice.
    3. Explain the current evidence supporting or opposing use of treatments for bipolar I depression.
    4. Develop evidence-based management plans for bipolar I depression.
  • Accreditation and Credit Designation Statements

    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ACCME: Forefront Collaborative designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABPN MOC: The American Board of Psychiatry and Neurology has reviewed A Portrait of Bipolar I Depression: Visualizing Improved Patient Care on World Bipolar Day and has approved this program as part of a comprehensive continuing medical education (CME) program, which is mandated by the ABMS as a necessary component of continuing certification.

    Nurse Practitioners
    This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

    This activity is approved for 1.0 contact hour (which includes 0.25 hour(s) of pharmacology).

  • CME/CE Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH Inc., and Allergan. 

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational grant from Allergan.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Bipolar depression remains a burden for patients living with bipolar I disorder. Therefore, faculty experts came together on World Bipolar Day in a call to action to the healthcare community to improve the diagnosis and treatment of bipolar I depression. In this 60-minute activity previously aired as a live broadcast, faculty review the diagnosis and treatment of a patient case, discussing the utility of tools in diagnosis and strategies to overcome common clinical challenges. An overview of treatments recommended for bipolar I depression is also provided.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME/CE activity:

    • Planners (Forefront Collaborative): Valerie Siclari, PhD and Megan Ragan
    • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
    • Faculty Planner: James Edgar Skye

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    Faculty Presenter: Larry Culpepper, MD, MPH

    • Royalty: UpToDate
    • Consulting Fee: AbbVie Pharmaceuticals, Acadia Pharmaceuticals, Allergan Pharmaceuticals, Eisai Pharmaceuticals, Takeda Pharmaceuticals 
    • Advisory Board: AbbVie Pharmaceuticals, Acadia Pharmaceuticals, Allergan Pharmaceuticals, Eisai Pharmaceuticals, Takeda Pharmaceuticals
    • Ownership Interest: M3 Information, LLC
    • Other: Receive payment from Physicians Postgraduate Press as Editor in Chief of the Primary Care Companion for CNS Diseases

    Faculty Presenter: Joseph F. Goldberg, MD, MS 

    • Royalty: American Psychiatric Publishing; Cambridge University Press
    • Consulting Fee: BioXcel; Otsuka; Neurocrine; Sunovion; Sage Pharmaceuticals
    • Speakers Bureau: AbbVie; Intracellular Therapies; Sunovion
    • Advisory Board: Otsuka; Sunovion; Neurocrine

    Faculty Presenter: Andrew A. Nierenberg, MD 

    • Royalty: UpToDate; Guilford Press
    • Consulting Fee: Alkermes; Clexio; Ginger.io; Merck; Neuronetics; NeuroRx; Sage; Sunovion
    • Contracted Research: Fitbit; Myriad

    Faculty Planner: Mary D. Moller, DNP, PhD(h), ARNP, PMHCNS-BC, CPRP, FAAN 

    • Speakers Bureau: Alkermes; Otsuka
    • Advisory Board: Teva

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    The target audience includes psychiatrists, primary care physicians (PCPs), nurse practitioners (NPs), and physician assistants (PAs) who care for patients with bipolar I disorder.

  • Learning Objectives

    Upon completion of this activity, learners should increase their ability to

    1. Distinguish bipolar I depression from unipolar depression earlier in patients.
    2. Incorporate tools to help diagnose bipolar I depression into routine practice.
    3. Explain the current evidence supporting or opposing use of treatments for bipolar I depression.
    4. Develop evidence-based management plans for bipolar I depression.
  • Accreditation and Credit Designation Statements

    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ACCME: Forefront Collaborative designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABPN MOC: The American Board of Psychiatry and Neurology has reviewed A Portrait of Bipolar I Depression: Visualizing Improved Patient Care on World Bipolar Day and has approved this program as part of a comprehensive continuing medical education (CME) program, which is mandated by the ABMS as a necessary component of continuing certification.

    Nurse Practitioners
    This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

    This activity is approved for 1.0 contact hour (which includes 0.25 hour(s) of pharmacology).

  • CME/CE Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH Inc., and Allergan. 

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an educational grant from Allergan.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/25/21